Stefan Größ

10.1k total citations · 3 hit papers
27 papers, 5.5k citations indexed

About

Stefan Größ is a scholar working on Molecular Biology, Cancer Research and Genetics. According to data from OpenAlex, Stefan Größ has authored 27 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Cancer Research and 6 papers in Genetics. Recurrent topics in Stefan Größ's work include Cancer, Hypoxia, and Metabolism (12 papers), Glioma Diagnosis and Treatment (6 papers) and Epigenetics and DNA Methylation (5 papers). Stefan Größ is often cited by papers focused on Cancer, Hypoxia, and Metabolism (12 papers), Glioma Diagnosis and Treatment (6 papers) and Epigenetics and DNA Methylation (5 papers). Stefan Größ collaborates with scholars based in United States, Germany and China. Stefan Größ's co-authors include Lenny Dang, Valeria R. Fantin, Shengfang Jin, Shinsan M. Su, Edward M. Driggers, Hyun Gyung Jang, Mark Bittinger, Kevin M. Marks, Katharine Yen and Marie C. Keenan and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Stefan Größ

24 papers receiving 5.4k citations

Hit Papers

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate 2009 2026 2014 2020 2009 2012 2010 1000 2.0k 3.0k

Peers

Stefan Größ
Shengfang Jin United States
Mark Bittinger United States
Katharine Yen United States
Shinsan M. Su United States
Kevin M. Marks United States
Marie C. Keenan United States
David R. Wise United States
Lenny Dang United States
Valeria R. Fantin United States
Ivan Kos Croatia
Shengfang Jin United States
Stefan Größ
Citations per year, relative to Stefan Größ Stefan Größ (= 1×) peers Shengfang Jin

Countries citing papers authored by Stefan Größ

Since Specialization
Citations

This map shows the geographic impact of Stefan Größ's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Größ with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Größ more than expected).

Fields of papers citing papers by Stefan Größ

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Größ. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Größ. The network helps show where Stefan Größ may publish in the future.

Co-authorship network of co-authors of Stefan Größ

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Größ. A scholar is included among the top collaborators of Stefan Größ based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Größ. Stefan Größ is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Größ, Stefan & Christal D. Sohl. (2021). Readying students for careers in industry: A guided inquiry activity to prepare students for success in biotechnology and pharmaceutical industry positions. Biochemistry and Molecular Biology Education. 49(3). 407–415. 3 indexed citations
2.
Zhang, Meng, Angelo Aguilar, Shilin Xu, et al.. (2021). Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression. Journal of Medicinal Chemistry. 64(14). 10333–10349. 16 indexed citations
3.
Nagaraja, Raj, Andrew Olaharski, Rohini Narayanaswamy, et al.. (2020). Preclinical toxicology profile of squalene epoxidase inhibitors. Toxicology and Applied Pharmacology. 401. 115103–115103. 17 indexed citations
4.
Padyana, Anil K., Stefan Größ, Lei Jin, et al.. (2019). Structure and inhibition mechanism of the catalytic domain of human squalene epoxidase. Nature Communications. 10(1). 99 indexed citations
5.
Gassaway, Brandon M., Rebecca Cardone, Anil K. Padyana, et al.. (2019). Distinct Hepatic PKA and CDK Signaling Pathways Control Activity-Independent Pyruvate Kinase Phosphorylation and Hepatic Glucose Production. Cell Reports. 29(11). 3394–3404.e9. 12 indexed citations
6.
Größ, Stefan & Thorsten Sellhorn. (2017). Der Wirtschaftsprüfer 2.0 im digitalen Öko-System. 1 indexed citations
7.
Marjon, Katya, Michael J. Cameron, Phong Quang, et al.. (2016). MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis. Cell Reports. 15(3). 574–587. 280 indexed citations
8.
Davis, Mindy I., Stefan Größ, Min Shen, et al.. (2014). Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1. Journal of Biological Chemistry. 289(20). 13717–13725. 72 indexed citations
9.
Ulanet, Danielle, Abhishek Jha, Sung Choe, et al.. (2014). Mesenchymal Phenotype Predisposes Lung Cancer Cells to Impaired Proliferation and Redox Stress in Response to Glutaminase Inhibition. PLoS ONE. 9(12). e115144–e115144. 39 indexed citations
10.
Größ, Stefan. (2013). Inequality and Emancipation : An Educational Approach. SHILAP Revista de lepidopterología. 2 indexed citations
12.
Davis, Mindy I., Rajan Pragani, Janeta Popovici-Müller, et al.. (2013). ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. Europe PMC (PubMed Central). 16 indexed citations
13.
Popovici-Müller, Janeta, Jeffrey O. Saunders, Francesco G. Salituro, et al.. (2012). Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo. ACS Medicinal Chemistry Letters. 3(10). 850–855. 160 indexed citations
14.
Koivunen, Peppi, Sung-Woo Lee, Christopher G. Duncan, et al.. (2012). Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 483(7390). 484–488. 566 indexed citations breakdown →
15.
DeLaBarre, Byron, Stefan Größ, Cheng Fang, et al.. (2011). Full-Length Human Glutaminase in Complex with an Allosteric Inhibitor. Biochemistry. 50(50). 10764–10770. 123 indexed citations
16.
Größ, Stefan, Rob A. Cairns, Mark D. Minden, et al.. (2010). Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. The Journal of Experimental Medicine. 207(2). 339–344. 558 indexed citations breakdown →
17.
Fantin, Valeria R., Lenny Dang, David W. White, et al.. (2010). Abstract 33: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Cancer Research. 70(8_Supplement). 33–33. 4 indexed citations
18.
Dang, Lenny, David W. White, Stefan Größ, et al.. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 462(7274). 739–744. 3067 indexed citations breakdown →
19.
Größ, Stefan & Martin Lamm. (2008). Sicherung des Vorsteuerabzugs bei digitalisierten Eingangsrechnungen. 57(9). 1 indexed citations
20.
Buiting, Karin, Stefan Größ, Y. Ji, et al.. (1998). Expressed copies of the MN7 (D15F37) gene family map close to the common deletion breakpoints in the Prader-Willi/Angelman syndromes. Cytogenetic and Genome Research. 81(3-4). 247–253. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026